Muthyala A, Sasidharan S, John KJ, Lal A, Mishra AK. Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2. World J Virol 2022; 11(5): 375-390 [PMID: 36188743 DOI: 10.5501/wjv.v11.i5.375]
Corresponding Author of This Article
Ajay K Mishra, FACP, MBBS, MD, Academic Fellow, Assistant Professor, Department of Cardiology, Saint Vincent Hospital, 123 Summer Street, Worcester, MA 01608, United States. ajay.mishra@stvincenthospital.com
Research Domain of This Article
Virology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virol. Sep 25, 2022; 11(5): 375-390 Published online Sep 25, 2022. doi: 10.5501/wjv.v11.i5.375
Utility of cardiac bioenzymes in predicting cardiovascular outcomes in SARS-CoV-2
Anjani Muthyala, Sandeep Sasidharan, Kevin John John, Amos Lal, Ajay K Mishra
Anjani Muthyala, Sandeep Sasidharan, Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA 01608, United States
Kevin John John, Department of Critical Care, Belivers Church Medical College Hospital, Thiruvalla 689103, Kerela, India
Amos Lal, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, United States
Ajay K Mishra, Department of Cardiology, Saint Vincent Hospital, Worcester, MA 01608, United States
Author contributions: Mishra AK and Muthyala A contributed to the conceptual design of the study; Muthyala A and Sasidharan S independently screened the articles and extracted the data; Muthyala A, Sasidharan S, Mishra AK contributed to write-up and submission of the study; Mishra AK, John KJ and Lal A reviewed the final manuscript; all authors reviewed and agreed with the final content of the article.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ajay K Mishra, FACP, MBBS, MD, Academic Fellow, Assistant Professor, Department of Cardiology, Saint Vincent Hospital, 123 Summer Street, Worcester, MA 01608, United States. ajay.mishra@stvincenthospital.com
Received: April 25, 2022 Peer-review started: April 25, 2022 First decision: May 31, 2022 Revised: June 12, 2022 Accepted: August 10, 2022 Article in press: August 10, 2022 Published online: September 25, 2022
ARTICLE HIGHLIGHTS
Research background
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is prevalent worldwide. Though lung injury is the most common presentation, cardiovascular dysfunction is seen on account of the widespread inflammation.
Research motivation
Cardiac biomarkers are released secondary to cardiovascular injury, and can be used as surrogate markers to gauge the disease severity.
Research objectives
To identify the role of individual biomarkers in diagnosing cardiac injury, and implications in determining prognosis and mortality.
Research methods
An extensive literature search was conducted for all studies on patients with COVID-19 associated cardiovascular injury and cardiac bioenzymes. Articles were screened using PubMed/Medline database, additionally reference citation analysis tool was also used. Eligible articles were then included in the study.
Research results
Cardiac troponin was seen as a robust diagnostic marker of cardiovascular injury across studies. Elevated troponin levels correlated with the level of disease severity. Similar results were seen alongside elevations in natriuretic peptides, irrespective of their prior diagnosis of heart failure.
Research conclusions
Multiple cardiac biomarkers can help predict the severity of disease and serve for prognostication purposes. Assessment of bioenzymes at admission and their serial monitoring can help predict mortality in patients with COVID-19.
Research perspectives
New data is emerging on novel biomarkers including soluble ST2, galectin-3, presepsin and copeptin which can further aid in diagnostic evaluation alongside troponins and natriuretic peptides.
